1st Feb 2011 07:00
Vectura Group plc
Appointment of Corporate Broker
Chippenham, UK, 1 February 2011 - Vectura Group plc (LSE: VEC) ("Vectura"), today announces the appointment of Peel Hunt LLP as Vectura's corporate broker and an adviser on financial matters with immediate effect.
- Ends -
For further enquiries, please contact:
Vectura Group plc |
|
Chris Blackwell, Chief Executive Anne Hyland, Chief Financial Officer Julia Wilson, Director of Investor Relations | Tel: +44 (0) 1249 667700 |
|
|
Financial Dynamics |
|
Ben Atwell Susan Quigley
| Tel: +44 (0) 20 7831 3113 |
Notes for Editors
About Vectura
Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD) a growing market that is currently estimated to be worth in excess of $25 billion. Vectura also develops products for other lung pathologies and non-respiratory diseases.
Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.
Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Otsuka. For further information, please visit Vectura's website at www.vectura.com.
Related Shares:
VEC.L